About Sialin
Sialin (SLC17A5) is a protein
from Homo sapiens identified by UniProt accession
Q9NRA2, 495 residues long.
MolForge cross-references it against 0 known binders and
119 disease associations.
Target properties
| Protein name | Sialin |
| UniProt accession | Q9NRA2 |
| Gene | SLC17A5 |
| Organism | Homo sapiens |
| Length | 495 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (119)
Diseases linked to this target (Open Targets).
- free sialic acid storage disease, infantile form · score 0.82
- Salla disease · score 0.81
- neurodegenerative disease · score 0.50
- intermediate severe Salla disease · score 0.45
- genetic disorder · score 0.41
- lysosomal storage disease · score 0.37
- hydrops fetalis · score 0.37
- Hydrops fetalis · score 0.37
- inborn errors of metabolism · score 0.37
- free sialic acid storage disease · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NRA2-F1 | alphafold | PREDICTED | 84.15 | — |
Amino-acid sequence (495 residues)
MRSPVRDLAR NDGEESTDRT PLLPGAPRAE AAPVCCSARY NLAILAFFGF FIVYALRVNL SVALVDMVDS NTTLEDNRTS KACPEHSAPI KVHHNQTGKK YQWDAETQGW ILGSFFYGYI ITQIPGGYVA SKIGGKMLLG FGILGTAVLT LFTPIAADLG VGPLIVLRAL EGLGEGVTFP AMHAMWSSWA PPLERSKLLS ISYAGAQLGT VISLPLSGII CYYMNWTYVF YFFGTIGIFW FLLWIWLVSD TPQKHKRISH YEKEYILSSL RNQLSSQKSV PWVPILKSLP LWAIVVAHFS YNWTFYTLLT LLPTYMKEIL RFNVQENGFL SSLPYLGSWL CMILSGQAAD NLRAKWNFST LCVRRIFSLI GMIGPAVFLV AAGFIGCDYS LAVAFLTIST TLGGFCSSGF SINHLDIAPS YAGILLGITN TFATIPGMVG PVIAKSLTPD NTVGEWQTVF YIAAAINVFG AIFFTLFAKG EVQNWALNDH HGHRH
Explore Sialin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets